biolitec AG
biolitec AG publishes unaudited financial statement for 2010/2011 – group revenue increases to 35.2 million Euros
biolitec AG / Key word(s): Statement 05.09.2012 / 17:04 --------------------------------------------------------------------- Jena, September 05th, 2012 - biolitec AG, Jena, listed on the Prime Standard of the Frankfurt Stock Exchange (ISIN DE0005213409), has published its unaudited financial statement for the fiscal year 2010/2011 in German on its corporate website www.biolitec.de. Thus the company responds to some shareholder's wishes who, on the Extraordinary General Meeting on August 30th 2012, declared themselves in favour of publishing the unaudited statement. At the same time, biolitec wants to provide the greatest possible transparency on the business development of the past years for its shareholders. Due to the unexpectedly demanding auditing work und the still not completed audit of the annual financial statement, biolitec has not received a final version of the annual financial statement yet. biolitec will publish the final financial figures for the fiscal year 2010/2011 immediately after the completion of the auditing work by the auditors of BDO. biolitec already decided to publish the first three quarters of the fiscal year 2011/2012 even without audited annual statement of accounts for 2010/2011, which has been closed with unaudited sales of 35.2 million Euros. In the fiscal year 2010/2011, the group revenue amounted to 35.2 million Euros (previous year: 30.4 million Euros), which equals an increase of 16%. Despite the positive development of sales, the group achieved a loss of -5.169 million Euros from the operating business (EBIT -6.472 million Euros) and was thus considerably under the previous year's level (previous year: EBIT -45 thousand Euros). The reasons therefore are basically rooted in a substantial rise of the general administrative expenses of -5.8 million Euros and additional currency losses of -1.5 million Euros. The administrative expenses of the prior and singular corrections of the US-American corporations' corporate values of 3.3 million Euros are therewith included. The sales for the Meditec segment were increased by 5.2 million Euros from 28.8 million Euros in the previous year to 34 million Euros. The sales in the pharmaceuticals segment of 1.3 million Euros were slightly under the previous year's level of 1.6 million Euros. As in the past years, the reduction of inventory values has been successfully continued (from 16.6 million Euros in the fiscal year 2009/2010 to 13.1 million Euros in 2010/2011). For the fiscal year 2011/2012, further reduction of inventories is planned. The gross profit increased by 1.1 million Euros compared to the previous year to Euro 20.6 million Euros. In the past financial year, biolitec's R&D expenditures amounted to 3.2 million Euros (previous year: 3.6 million Euros) or 9.2% of sales. Significant revenues of biolitec AG were achieved in Europe and North America. The sales in North America amounted to 12.5 million Euros and were thus 7% higher than those in the previous fiscal year. The sales in Europe reached 16.7 million Euros (previous fiscal year: 14.2 million Euros). In Asia/rest of the world biolitec could achieve a significant increase of 41%. The main generators of revenue were LIFE(TM), biolitec's laser treatment of BPH, and the endoluminal laser treatment for veins (ELVeS(TM)). Due to the launching of new, innovative products, as for example HeLP(TM) - a new outpatient and pain-free treatment for the atrophy of haemorrhoidal arteries - biolitec is able to compete and consolidate its position in key markets worldwide. The TWISTER(TM)-fiber defends its position as preferred treatment method for the benign prostate hyperplasia and is still the first choice for numerous specialists. The ELVeS(R) RADIAL-fiber has been highlighted in several presentations and publications as state-of-the-art treatment for veins. The preliminary sales figures for the financial year 2011/2012 are also already available and amount to 40.27 million Euros for the biolitec group. biolitec AG expects growth to be sustained for the coming fiscal year 2012/13, biolitec expects growth to be sustained. About biolitec(R) biolitec(R) AG is one of the leading companies worldwide in the field of medical laser treatments und the only provider that possesses all relevant core competencies - photosensitizers, laser devices and optical fibres - in the field of photodynamic therapy (PDT). Besides the laser treatment of cancer with Foscan(R), biolitec(R) primarily researches on minimally-invasive and gentle laser treatments and markets them. ELVeS Radial(TM) (Endo Laser Vein System) the laser system is most often used worldwide for the treatment of varicose veins. Ceralas(R) HPD laser therapy enables a gentle treatment of e.g. benign prostatic hyperplasia (BPH) in urology. Gentle laser treatments in the fields of proctology, ENT, orthopaedics, gynaecology as well as ophtalmology also belong to the business field of biolitec(R). biolitec(R) is listed in the Prime Standard (ISIN DE0005213409). Further information at www.biolitec.de. Investor Relations Jörn Gleisner Telephone +49 (0) 69 / 959083-20 Telefax +49 (0) 69 / 959083-99 E-Mail: joern.gleisner@biolitec.com The information does not constitute an offer of or an invitation by or on behalf of biolitec AG or any of its subsidiaries to subscribe for or purchase securities of biolitec AG or any of its subsidiaries. In particular, the information contained does not constitute an offer of securities for sale or solicitation of an offer to buy securities in the United States of America. End of Corporate News --------------------------------------------------------------------- 05.09.2012 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: biolitec AG Otto-Schott-Str.15 07745 Jena Germany Phone: +49 (0) 3641 519 53 0 Fax: +49 (0) 3641 519 53 33 E-mail: info@biolitec.de Internet: www.biolitec.de ISIN: DE0005213409 WKN: 521340 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart End of News DGAP News-Service --------------------------------------------------------------------- 184322 05.09.2012
Latest News
Latest Reports
Upcoming Events
No Events found
Webcasts
No Webcasts found